Atomoxetine Other names: (R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine

Chemical formula: C₁₇H₂₁NO  Molecular mass: 255.355 g/mol  PubChem compound: 54841

Therapeutic indications

Atomoxetine is indicated for:

Attention-Deficit/Hyperactivity Disorder (ADHD)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older and in adolescents as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician or child/adolescent psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Attention-Deficit/Hyperactivity Disorder (ADHD)

Population group: only adults (18 years old or older)

Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.

In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and atomoxetine should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Atomoxetine is contraindicated in the following cases:

Monoamine oxidase inhibitors (MAOI)

Monoamine oxidase inhibitors (MAOIs)

Narrow-angle glaucoma

Angle-closure glaucoma

Severe cardiovascular disorders, cerebrovascular disorders

at least one of
Severe pulmonary hypertension
Heart failure
Occlusion of artery
Angina
Congenital heart disease
Cardiomyopathy
Myocardial infarction
Cardiac channelopathy
Arrhythmia
Cerebral arterial aneurysm
CVA - Cerebrovascular accident

Pheochromocytoma

Phaeochromocytoma

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.